ValuEngine downgraded shares of Endo International (NASDAQ:ENDP) (TSE:ENL) from a buy rating to a hold rating in a research report released on Tuesday.

A number of other brokerages have also commented on ENDP. Citigroup upgraded shares of Endo International from a neutral rating to a buy rating and set a $11.00 price target for the company in a research note on Wednesday, June 27th. Mizuho lifted their price target on shares of Endo International to $17.00 and gave the stock a neutral rating in a research note on Tuesday, August 14th. TheStreet upgraded shares of Endo International from a d rating to a c- rating in a research note on Monday, August 20th. Canaccord Genuity set a $7.00 price target on shares of Endo International and gave the stock a hold rating in a research note on Tuesday, May 8th. Finally, BidaskClub upgraded shares of Endo International from a strong sell rating to a sell rating in a research note on Wednesday, May 16th. Two analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have given a buy rating and two have issued a strong buy rating to the stock. The company presently has a consensus rating of Hold and an average price target of $13.60.

NASDAQ:ENDP opened at $17.13 on Tuesday. The stock has a market cap of $3.84 billion, a price-to-earnings ratio of 5.51, a PEG ratio of 3.29 and a beta of 0.73. The company has a debt-to-equity ratio of -132.64, a current ratio of 1.07 and a quick ratio of 0.91. Endo International has a fifty-two week low of $5.27 and a fifty-two week high of $17.46.

Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings data on Wednesday, August 8th. The company reported $0.76 earnings per share for the quarter, beating analysts’ consensus estimates of $0.54 by $0.22. The business had revenue of $714.70 million during the quarter, compared to analyst estimates of $679.72 million. Endo International had a negative net margin of 34.72% and a positive return on equity of 237.45%. Endo International’s revenue was down 18.4% compared to the same quarter last year. During the same period last year, the business earned $0.93 EPS. equities research analysts expect that Endo International will post 2.6 earnings per share for the current year.

In related news, Director Roger H. Kimmel sold 26,074 shares of the firm’s stock in a transaction that occurred on Tuesday, August 14th. The shares were sold at an average price of $15.90, for a total value of $414,576.60. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 0.80% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Xact Kapitalforvaltning AB boosted its holdings in shares of Endo International by 44.5% in the first quarter. Xact Kapitalforvaltning AB now owns 29,215 shares of the company’s stock worth $174,000 after buying an additional 9,000 shares during the last quarter. Neuburgh Advisers LLC boosted its holdings in shares of Endo International by 84.2% in the first quarter. Neuburgh Advisers LLC now owns 36,234 shares of the company’s stock worth $215,000 after buying an additional 16,566 shares during the last quarter. Riverhead Capital Management LLC boosted its holdings in shares of Endo International by 83.9% in the first quarter. Riverhead Capital Management LLC now owns 41,218 shares of the company’s stock worth $245,000 after buying an additional 18,800 shares during the last quarter. Tyers Asset Management LLC boosted its holdings in shares of Endo International by 84.2% in the first quarter. Tyers Asset Management LLC now owns 46,116 shares of the company’s stock worth $274,000 after buying an additional 21,084 shares during the last quarter. Finally, Flinton Capital Management LLC boosted its holdings in shares of Endo International by 84.2% in the first quarter. Flinton Capital Management LLC now owns 55,998 shares of the company’s stock worth $333,000 after buying an additional 25,602 shares during the last quarter. 98.43% of the stock is currently owned by institutional investors.

About Endo International

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Further Reading: Leveraged Buyout (LBO)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.